Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...
Zacks Investment Research on MSN4h
Bayer's sNDA for Kerendia Label Expansion Gets FDA's Priority ReviewBayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...
The PREDICT-HFpEF tool predicts cardiovascular risk, and finerenone remains effective for heart failure across baseline risk levels.
Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...
AI-assisted diagnosis of asymptomatic left ventricular dysfunction may detect disease early and thereby expedite treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback